`
`
`
`
`Exhibit B
`
`
`
`
`
`
`
`Case: 1:16-cv-00651 Document #: 89 Filed: 01/26/18 Page 1 of 8 PageID #:2546Case: 1:16-cv-00651 Document #: 99-2 Filed: 05/03/18 Page 2 of 9 PageID #:2584
`
`HOSPIRA, INC.
`
`
`
`
`
`FRESENIUS KABI USA, LLC
`
`
`
`
`
`v.
`
`
`
`
`
`
`
`
`
`
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE NORTHERN DISTRICT OF ILLINOIS
`EASTERN DIVISION
`
`)
`)
`)
`)
`)
`)
`)
`)
`
`)
`
`
`JOINT MOTION TO ENTER STIPULATION
`
`
`
`
`
`C.A. No. 16-cv-651
`C.A. No. 17-cv-7903
`
`Hon. Judge Rebecca R. Pallmeyer
`
`Plaintiff,
`
`Defendant.
`
`Plaintiff Hospira, Inc. and Defendant Fresenius Kabi USA, LLC (“the parties”)
`
`respectfully request that the Court enter the attached Joint Stipulation regarding infringement and
`
`modifications to the case schedule. In support of this Motion, the parties state:
`
`1. On January 4, 2018, the Court entered a Revised Scheduling Order that set deadlines for,
`
`among other things, Fresenius Kabi’s invalidity contentions, Hospira’s responses thereto,
`
`expert discovery, and a final pre-trial order. (Case No. 17-7903, D.I. 23.)
`
`2. On January 5, 2018, Fresenius Kabi served its Amended Final Invalidity Contentions.
`
`3. On January 16, 2018, following discussions with Fresenius Kabi about Hospira’s
`
`objections to the contentions, Hospira moved to strike certain theories raised in Fresenius
`
`Kabi’s Amended Final Contentions. (D.I. 81.) In the alternative, Hospira requested that
`
`the case schedule be extended to allow Hospira time to investigate those theories.
`
`4. As discussed at the January 25, 2018, status hearing, the parties have reached an
`
`agreement to resolve the dispute set forth in Hospira’s Motion to Strike. The details of
`
`the parties’ agreement is set forth in the attached Joint Stipulation.
`
`
`
`
`
`
`
`Case: 1:16-cv-00651 Document #: 89 Filed: 01/26/18 Page 2 of 8 PageID #:2547Case: 1:16-cv-00651 Document #: 99-2 Filed: 05/03/18 Page 3 of 9 PageID #:2585
`
`WHEREFORE, the parties request that the Court enter the Stipulation attached as Exhibit
`
`A.
`
`
`Dated: January 26, 2018
`
`Respectfully submitted,
`
`/s/ Bradford P. Lyerla
`
`Bradford P. Lyerla
`Sara T. Horton
`Yusuf Esat
`Ren-How Harn
`JENNER & BLOCK LLP
`353 N. Clark Street
`Chicago, IL 60654-3456
`(312) 222-9350
`blyerla@jenner.com
`shorton@jenner.com
`yesat@jenner.com
`rharn@jenner.com
`
`Attorneys for Plaintiff
`Hospira, Inc.
`
`
`
`
`
`
`
`
`
`
`
`/s/ Joel M. Wallace
`
`Imron T. Aly
`Joel M. Wallace
`Emily M. Peña
`Tara L. Feld
`233 South Wacker Drive, Suite 7200
`Chicago, Illinois 60606
`(312) 258-5500
`ialy@schiffhardin.com
`jwallace@schiffhardin.com
`epena@schiffhardin.com
`tkurtis@schiffhardin.com
`
`Ahmed M.T. Riaz (pro hac vice)
`666 Fifth Avenue, 17th Floor
`New York, NY 10103
`(212) 753-5000
`ariaz@schiffhardin.com
`
`Attorneys for Defendant Fresenius Kabi USA,
`LLC
`
`
`
`
`
`
`
`
`2
`
`
`
`
`
`Case: 1:16-cv-00651 Document #: 89 Filed: 01/26/18 Page 3 of 8 PageID #:2548Case: 1:16-cv-00651 Document #: 99-2 Filed: 05/03/18 Page 4 of 9 PageID #:2586
`
`CERTIFICATE OF SERVICE
`
`I, Yusuf Esat, an attorney at the law firm of Jenner & Block LLP, hereby certify that on
`
`January 26, 2018, I caused a true and correct copy of the foregoing JOINT MOTION TO
`
`ENTER STIPULATION to be electronically served on counsel of record via the Court’s
`
`CM/ECF system.
`
`
`
`
`
`/s/ Yusuf Esat
` Yusuf Esat
`
`
`
`
`
`3
`
`
`
`
`
`
`
`
`
`Case: 1:16-cv-00651 Document #: 89 Filed: 01/26/18 Page 4 of 8 PageID #:2549Case: 1:16-cv-00651 Document #: 99-2 Filed: 05/03/18 Page 5 of 9 PageID #:2587
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit A
`
`
`
`4
`
`
`
`
`
`Case: 1:16-cv-00651 Document #: 89 Filed: 01/26/18 Page 5 of 8 PageID #:2550Case: 1:16-cv-00651 Document #: 99-2 Filed: 05/03/18 Page 6 of 9 PageID #:2588
`
`HOSPIRA, INC.
`
`
`
`
`
`FRESENIUS KABI USA, LLC
`
`
`
`
`
`v.
`
`
`
`
`
`
`
`
`
`
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE NORTHERN DISTRICT OF ILLINOIS
`EASTERN DIVISION
`
`)
`)
`)
`)
`)
`)
`)
`)
`
`)
`
`
`[PROPOSED] JOINT STIPULATION
`
`
`
`
`
`C.A. No. 16-cv-651
`C.A. No. 17-cv-7903
`
`Hon. Judge Rebecca R. Pallmeyer
`
`Plaintiff,
`
`Defendant.
`
`This stipulation is made by and between Plaintiff Hospira, Inc. (“Hospira”) and
`
`Defendant Fresenius Kabi USA, LLC (“Fresenius Kabi”).
`
`WHEREAS, on January 15, 2016, Hospira filed a Complaint against Fresenius Kabi for
`
`infringement of U.S. Patent Nos. 8,242,158; 8,338,470; 8,455,527; and 8,648,106, captioned
`
`Hospira, Inc. v. Fresenius Kabi USA, LLC, C.A. No. 16-cv-651 (“the First Action”), related to
`
`Fresenius Kabi’s submission of Amended New Drug Application No. 208129 (“ANDA
`
`208129”) to the Food and Drug Administration seeking approval to market dexmedetomidine
`
`hydrochloride for injection, 80 mcg/20 mL, 200 mcg/50 mL, and 400 mcg/100 mL (“Fresenius
`
`Kabi’s Proposed ANDA Products”);
`
`WHEREAS, on November 1, 2017, Hospira filed a Complaint against Fresenius Kabi for
`
`infringement of later-issued U.S. Patent No. 9,616,049, captioned Hospira, Inc. v. Fresenius
`
`Kabi USA, LLC, C.A. No. 17-cv-7903 (“the Second Action”), related to Fresenius Kabi’s
`
`submission of ANDA 208129 to the Food and Drug Administration seeking approval to market
`
`Fresenius Kabi’s Proposed ANDA Products;
`
`
`
`5
`
`
`
`
`
`Case: 1:16-cv-00651 Document #: 89 Filed: 01/26/18 Page 6 of 8 PageID #:2551Case: 1:16-cv-00651 Document #: 99-2 Filed: 05/03/18 Page 7 of 9 PageID #:2589
`
`WHEREAS, on December 1, 2017, Fresenius Kabi filed a Counterclaim in the Second
`
`Action asking for declaratory judgment of non-infringement and invalidity of U.S. Patent No.
`
`9,320,712 and Hospira answered the Counterclaim on December 22, 2017;
`
`WHEREAS, on November 27, 2017, the Court issued its Claim Construction Opinion
`
`and Order (D.I. 69) in the First Action, which the parties agree applies to the same claim terms in
`
`the Second Action;
`
`WHEREAS, the parties jointly agreed to limit the number of claims asserted from each
`
`patent in the First and Second Action to simplify issues for expert discovery and trial;
`
`It is hereby STIPULATED AND AGREED, subject to the approval of the Court, that:
`
`1.
`
`Hospira asserts only these claims from all asserted patents and waives the
`
`assertion of all other claims: claims 6, 8, and 13 of U.S. Patent No. 8,455,527; claims 6 and 9 of
`
`U.S. Patent No. 8,648,106; claim 5 of U.S. Patent No. 9,320,712 and claims 4, 8, 13, and 14 of
`
`U.S. Patent No. 9,616,049. Fresenius Kabi will not assert counterclaims of non-infringement or
`
`invalidity of any other claims.
`
`2.
`
`Fresenius Kabi hereby stipulates, in the First Action, that Fresenius Kabi’s
`
`Proposed ANDA Products described in ANDA 208129, and/or the use of Fresenius Kabi’s
`
`Proposed ANDA Products, would meet the limitations of claim 6 of U.S. Patent No. 8,455,527;
`
`and claims 6 and 9 of U.S. Patent No. 8,648,106 under 35 U.S.C. § 271(e) under the claim
`
`constructions entered in this action, to the extent these claims are valid and enforceable. This
`
`Stipulation does not limit or otherwise affect Fresenius Kabi’s ability to defend against Hospira’s
`
`asserted claims on any other ground, including, but not limited to, asserted defenses of invalidity
`
`and/or unenforceability.
`
`
`
`6
`
`
`
`
`
`Case: 1:16-cv-00651 Document #: 89 Filed: 01/26/18 Page 7 of 8 PageID #:2552Case: 1:16-cv-00651 Document #: 99-2 Filed: 05/03/18 Page 8 of 9 PageID #:2590
`
`3.
`
`Fresenius Kabi hereby stipulates, in the Second Action, that Fresenius Kabi’s
`
`Proposed ANDA Products described in ANDA 208129, and/or the use of Fresenius Kabi’s
`
`Proposed ANDA Products, would meet the limitations claim 5 of U.S. Patent No. 9,320,712 and
`
`claims 4, 8, 13, and 14 of U.S. Patent No. 9,616,049 under 35 U.S.C. § 271(e) under the claim
`
`constructions entered in this action, to the extent these claims are valid and enforceable. This
`
`Stipulation does not limit or otherwise affect Fresenius Kabi’s ability to defend against Hospira’s
`
`asserted claims on any other ground, including, but not limited to, asserted defenses of invalidity
`
`and/or unenforceability.
`
`
`Fresenius Kabi withdraws the following invalidity theories that are the subject of
`
`4.
`
`Hospira’s Motion to Strike Untimely Invalidity Contentions (see D.I. 81 at 5-6):
`
` Alleged invalidating prior use under 35 U.S.C. § 102(b) based on
`Investigational New Drug Application (“IND”) No. 32,934 (Pages 35-37
`of Fresenius Kabi’s Amended Final Invalidity Contentions); and
`
` Alleged prior invention under Section 102(g) based on work relating to the
`IND (Pages 120-125 of Fresenius Kabi’s Amended Final Invalidity
`Contentions).
`
`The Revised Scheduling Order (Case No. 17-7903, D.I. 23) is amended as
`
`
`5.
`
`follows:
`
`Event
`
`Fresenius Kabi’s Non-Infringement Contentions (of ‘527 Claims
`8 and 13)
`
`Hospira’s Response to Fresenius Kabi’s Amended Final
`Invalidity Contentions
`
`Close of Fact Discovery
`
`Opening expert reports [Pl. Infringement, Secondary
`Considerations; Def. Invalidity]
`
`
`Date
`
`March 26, 2018
`
`March 26, 2018
`
`April 2, 2018
`
`April 16, 2018
`
`
`
`7
`
`
`
`
`
`Case: 1:16-cv-00651 Document #: 89 Filed: 01/26/18 Page 8 of 8 PageID #:2553Case: 1:16-cv-00651 Document #: 99-2 Filed: 05/03/18 Page 9 of 9 PageID #:2591
`
`Responsive expert reports [Pl. Validity; Def. Non-
`infringement, Secondary Considerations]
`
`Close expert discovery
`
`Hospira’s draft Pre-trial Order
`
`Final Pre-trial Order
`
`Bench Trial
`
`Fresenius Kabi Will Not Launch (Without Opinion) Before
`
`
`May 21, 2018
`
`June 13, 2018
`
`June 20, 2018
`
`July 2, 2018
`
`July 16-20, 2018
`
`
`
`8
`
`
`
`
`
`